Scholarly record
IN VIVO EVALUATION OF THE BIOAVAILABILITY OF THE HYDROXIPROPYL-?-CYCLODEXTRIN/AMIODARONE INCLUSION COMPLEX
Abstract
Amiodarone (AMD) is an antiarrhythmic agent included in the 2nd class according to the biopharmaceutical classification of drug substances. The oral bioavailability of AMD in conventional pharmaceutical formulations exhibits large interindividual variations due to the rapid dealkylation of the molecule to desethylaminodarone (inactive metabolite) and due to low hydrosolubility. The complexation of the drug substance in the central cavity of various kinds of cyclodextrins is one of the most effective methods for optimizing the oral bioavailability of drug substances such as AMD, and it can be accomplished by complexation with hydroxypropyl-?-cyclodextrin (HP-?-CD). The objective of the study was to evaluate the influence of complexation on the oral bioavailability of AMD. The HP-?-CD/AMD inclusion complex was prepared in a 1:1 molar ratio, using the lyophilization method. It was characterized in terms of physico-chemical proprieties, pharmacokinetics, release kinetics, and in vivo bioavailability. The study was conducted according to the legislation in force, using male, Wistar, white mice. The animals were grouped in 2 batches: Lot 1 (control batch) which received AMD·HCL and Lot 2 (positive control batch) which received HP-?-CD/AMD. The analysis of AMD peak plasma concentrations for AMD·HCl (Cmax = 165.67 ± 80.21 ng/mL) and HP-?-CD/AMD (Cmax = 249.67 ± 94.50ng / mL) proved that HP-?-CD/AMD generates 1.5-fold higher average plasma concentrations and therefore those concentration levels are released concurrently. The analysis of areas under the curve for the variation of AMD plasma concentration in time (AUC0-t), showed that the values were approximately 1.15-fold higher for HP-?-CD/AMD (AUC0-t = 0 ± 2.2h) than for AMD·HCl (AUC0-t = 5.5 ± 1.9h). In conclusion, the results obtained confirmed that HP-?-CD is a type of cyclodextrin that can function as the host molecule for AMD in order to optimize oral bioavailability through formulation in modified-release oral therapeutic systems.
Publication Impact Profile
Publication details
References10
Van Herendael H. & Dorian P. Amiodarone for the Treatment and Prevention of Ventricular Fibrillation and Ventricular Tachycardia. Vascular Health and Risk Management, New Zealand, vol. 6, pp. 465-472, 2010.
Shayeganpour A., Hamdy D.A. & Brocks D.R. Pharmacokinetics of desethylamiodarone in the rat after its administration as the performed metabolite, and after administration of amiodarone. Biopharmaceutics & Drug Disposition, England, vol. 29/issue 3, pp. 159-166, 2008.
Wolkove N. & Baltzan M. Amiodarone pulmonary toxicity. Canadian journal of respiratory, critical care, and sleep medicine, England, vol. 16, pp. 43-48, 2009.
Lalatsa A. & Barbu E. Carbohydrate Nanoparticles for Brain Delivery. International Review of Neurobiology, United States, vol. 130, pp. 2-320, 2016.
Van der Manakker F., Vermonden T., Van Nostrum C.F. & Hennink W.E. Cyclodextrin based polymeric materials: synthesis, properties and pharmaceutical/biomedical application. Biomacromolecules, United States, vol. 10, pp. 3157-3175, 2009.
Jambhekar SS. & Breen P. Cyclodextrins in Pharmaceutical formulations II: solubilization, binding constant and complexation efficiency. Drug discovery today Biosilico, England, vol. 21/issue 2, pp. 363-368, 2016.
Gould S. & Scott RC. 2-hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology review. Food and chemical toxicology, England, vol. 43/issue 10, pp. 1451-1459, 2005.
Păduraru O.M., Bosînceanu A., Țântaru G. & Vasile C. Effect of hydroxipropyl-β-cyclodextrin on the solubility of an antiarrhytmic agent. Industrial & engineering chemistry research, United States, vol. 52, pp. 2174-2181, 2013.
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.
Crețeanu A., Țântaru G., Vieriu M., Panainte A.D. & Ochiuz L. Development and validation of a method used for quantitative determination of amiodarone hydrocloride in blood serum by HPLC-MS-MS. The Medical-Surgical Journal, Romania, vol. 2, pp. 427-433, 2017.
View or Download full articleAccess options
SWS access login
Login as SWS Scientific CommitteeLogin as SWS Scientific PartnerLogin as SWS AuthorAuthors and approved SWS contributors will read and export their own linked papers after identity matching by SWS profile, email and SGEM GlobalID.
For librarian assistance: [email protected]
Purchase Instant Access
- Article can be downloaded after successful payment.
- Article may be used according to SWS library access terms.
- Article cannot be redistributed.
